Production (Stage)
Chemomab Therapeutics Ltd.
CMMB
$1.23
$0.032.50%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -7.50M | -15.47M | -24.22M | -31.30M |
| Total Depreciation and Amortization | -- | 35.00K | 51.00K | 67.00K | 61.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 368.00K | 1.01M | 1.49M | 2.82M |
| Change in Net Operating Assets | -- | -1.84M | -2.02M | -948.00K | 4.57M |
| Cash from Operations | -- | -8.94M | -16.43M | -23.61M | -23.85M |
| Capital Expenditure | -- | 0.00 | -2.00K | -3.00K | -55.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 5.72M | 1.45M | 15.88M | 31.64M |
| Cash from Investing | -- | 5.72M | 1.45M | 15.88M | 31.58M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 2.14M | 3.50M | 3.50M | 410.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -1.22M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 2.14M | 3.50M | 3.50M | -808.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -1.09M | -11.47M | -4.23M | 6.93M |